Path Towards Precision Medicine through Exploring the Enigma of Unknown Genes in Epithelial Ovarian Cancer
DOI:
https://doi.org/10.58445/rars.1434Keywords:
Epithelial Ovarian Cancer, Genes, molecular biologyAbstract
Ovarian cancer can be dangerous as it does not show symptoms until it reaches advanced stages in some cases when there is little that can be done except provide relief only. This research aims at determining how unknown genes contribute towards Epithelial Ovarian Cancer (EOC), studying their molecular biology modes of action, significance and if they can be used for therapeutic purposes. We hypothesize that there are currently unidentified key genes that play critical roles in the development and progression of epithelial ovarian cancer . These uncharacterized genetic factors likely contribute significantly to the complexity of the disease. By uncovering these elusive genes, we expect to gain important insights into the underlying mechanisms driving EOC pathogenesis. Using publicly available CRISPR datasets through the Cancer Dependency Map, my study reveals promising new pathways for precision medicine, offering hope for more effective treatments and improved patient outcomes. Finding and describing these genes could help create new treatments that work better and help patients more. Also, this research might uncover new ways to spot EOC letting doctors treat it sooner and save more lives. What we learn about how EOC works at a tiny level can help doctors pick the right treatment for each patient based on their genes. In the end, what we find out could help us understand ovarian cancer better. This could lead to new ways to treat it and take care of patients.
References
Desai, A., Xu, J., Aysola, K., Qin, Y., Okoli, C., Hariprasad, R., ... & Rao, V. N. (2014). Epithelial ovarian cancer: An overview. World journal of translational medicine, 3(1), 1-8.
Cantuaria, G., Singh, K., Grizzle, W., Landen, C., Partridge, E. E., Rice, V. M., ... & Rao, V. N. (2016). Molecular characterization of epithelial ovarian cancer. International journal of molecular sciences, 17(12), 2113.
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., ... & Skates, S. J. (2016). Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet, 387(10022), 945-956.
Buys, S. S., Partridge, E., Black, A., Johnson, C. C., Lamerato, L., Isaacs, C., ... & Prorok, P. C. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. Jama, 305(22), 2295-2303.
Pinsky, P. F., Yu, K., Kramer, B. S., Black, A., Buys, S. S., Partridge, E., ... & Prorok, P. C. (2016). Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecologic oncology, 143(2), 270-275.
Ross, J. S., Ali, S. M., Wang, K., Palmer, G., Yelensky, R., Lipson, D., ... & Stephens, P. J. (2013). Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecologic oncology, 130(3), 554-559.
Kurman, R. J., & Shih, I. M. (2016). The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. The American journal of pathology, 186(4), 733-747.
Della Pepa, C., Tonini, G., Santini, D., Losito, S., Pisano, C., di Napoli, M., ... & Pignata, S. (2015). Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer treatment reviews, 41(2), 136-143.
Jones, S., Wang, T. L., Kurman, R. J., Nakayama, K., Velculescu, V. E., Vogelstein, B., ... & Shih, I. M. (2012). Low-grade serous carcinomas of the ovary contain very few point mutations. The Journal of pathology, 226(3), 413-420.
Vereczkey, I., Serester, O., Dobos, J., Gallai, M., Szakács, O., Szentirmay, Z., & Tóth, E. (2011). Molecular characterization of 103 ovarian serous and mucinous tumors. Pathology & Oncology Research, 17(3), 551-559.
Hogg, R., & Friedlander, M. (2004). Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. Journal of Clinical Oncology, 22(7), 1315-1327.
Finch, A., Beiner, M., Lubinski, J., Lynch, H. T., Moller, P., Rosen, B., ... & Narod, S. A. (2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. Jama, 296(2), 185-192.
Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., ... & Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama, 304(9), 967-975.
Marchetti, C., De Felice, F., Palaia, I., Perniola, G., Musella, A., Palaia, I., ... & Panici, P. B. (2014). Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC women's health, 14(1), 1-8.
Panici, P. B., Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., ... & Torri, V. (2005). Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. JNCI: Journal of the National Cancer Institute, 97(8), 560-566
Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Baker AC, Marlow SE, Hirozane-Kishikawa T, Hill DE, Vidal M, Johannessen CM, Kryukov GV, Park RW, Garraway LA, Golub TR, Root DE, Hahn WC. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):12372-7. doi: 10.1073/pnas.1109363108. Epub 2011 Jun 27. PMID: 21746896; PMCID: PMC3136311
Kuo, K. T., et al. "Mutations in the KRAS Gene in Low-Grade Serous Ovarian Carcinoma." Journal of Clinical Oncology, 2015.
Cancer Genome Atlas Research Network. "Integrated Genomic Analyses of Ovarian Carcinoma." Nature, 2011.
Ledermann, J. A., et al. "Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer." New England Journal of Medicine, 2014.
Morrissey, C., et al. "Genomic Alterations in Ovarian Cancer: A Review." Cancer Treatment Reviews, 2018.
Slamon, D. J., Leyland-Jones, B., Shak, S., et al. "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2." New England Journal of Medicine, vol. 344, no. 11, 2001, pp. 783-792.
Kumar, A., et al. "The Role of MicroRNAs in Ovarian Cancer: A Review." Journal of Ovarian Research, vol. 9, no. 1, 2016, pp. 1-10.
Bast, R. C., et al. "Biomarkers and New Technologies for Early Detection of Ovarian Cancer." Journal of Clinical Oncology, vol. 33, no. 16, 2015, pp. 1845-1850.
Friedlander, M. L., et al. "The Role of Surgery in the Management of Epithelial Ovarian Cancer." The Lancet Oncology, vol. 15, no. 12, 2014, pp. e602-e610.
Gonzalez, B. O., et al. "Genetic and Epigenetic Alterations in Ovarian Cancer: Implications for Therapy." Cancer Treatment Reviews, vol. 41, no. 1, 2015, pp. 1-10.
Karam, A., et al. "The Role of Immunotherapy in Ovarian Cancer: Current Status and Future Directions." Gynecologic Oncology, vol. 143, no. 2, 2016, pp. 275-283.
Liu, Y., et al. "The Impact of BRCA1 and BRCA2 Mutations on Ovarian Cancer Survival." Cancer Epidemiology, Biomarkers & Prevention, vol. 25, no. 3, 2016, pp. 493-500.
Miller, R. E., et al. "Targeting the Tumor Microenvironment in Ovarian Cancer: A Review." Frontiers in Oncology, vol. 8, 2018, Article 537.
Oza, A. M., et al. "Efficacy and Safety of Olaparib in Patients with BRCA1 or BRCA2 Mutations and Advanced Ovarian Cancer." New England Journal of Medicine, vol. 376, no. 25, 2017, pp. 2467-2477.
Rosen, B., et al. "The Role of Genetic Testing in Women with Ovarian Cancer." Journal of Clinical Oncology, vol. 34, no. 11, 2016, pp. 1274-1280.
Shih, I. M., et al. "The Pathogenesis of Ovarian Cancer: A Review." American Journal of Pathology, vol. 186, no. 4, 2016, pp. 733-747.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. cell, 144(5), 646-674.
Vogelstein, B., & Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nature medicine, 10(8), 789-799.
Croce, C. M. (2008). Oncogenes and cancer. New England Journal of Medicine, 358(5), 502-511.
Sharma, S. V., et al. "HER2-Targeted Therapy: A New Era in the Treatment of HER2-Positive Breast Cancer." Nature Reviews Clinical Oncology, vol. 11, no. 5, 2014, pp. 301-313.
Eilers, M., & Eisenman, R. N. (2008). "Myc's Many Faces." Cell, 143(1), 13-17.
Dang, C. V. (2012). "MYC on the Path to Cancer." Cell, 149(1), 22-35.
Shalem, O., et al. "Genome-scale CRISPR-Cas9 knockout screening in human cells." Science, vol. 343, no. 6166, 2015, pp. 84-87.
Doudna, J. A., & Charpentier, E. "The new frontier of genome engineering with CRISPR-Cas9." Science, vol. 346, no. 6213, 2014, pp. 1258096.
Hsu, P. D., et al. "Development and Applications of CRISPR-Cas9 for Genome Engineering." Cell, vol. 157, no. 6, 2014, pp. 1262-1278.
Jinek, M., et al. "A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity." Science, vol. 337, no. 6096, 2012, pp. 816-821.
Downloads
Posted
Categories
License
Copyright (c) 2024 Preesha Kothari
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.